Disease · MONDO_0021068

ovarian neoplasm

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. ovarian neoplasm. Diseases, record MONDO_0021068. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021068

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: ovarian neoplasm; Open Targets
Open Targets ID: MONDO_0021068; Open Targets
Other names: NEOPL OVARIAN, Neoplasm, Ovarian, Neoplasm, Ovary, Neoplasms, Ovarian, Neoplasms, Ovary, OVARIAN NEOPL, OVARY NEOPL, Ovarian Neoplasms, Ovary Neoplasms, neoplasm of ovary, neoplasm of the ovary, ovarian tumor, ovarian tumors, ovarian tumour, ovarian tumours, ovary neoplasm, ovary neoplasm (disease), ovary tumor, ovary tumour, tumor of ovary, tumor of the ovary, tumour of ovary, tumour of the ovary; Open Targets
NCI Thesaurus: C4984; NCI Thesaurus
Highest stage of its drugs: Approval, for 13 of its 17 drugs, from EMA Human Drugs and PMDA; Open Targets

Drugs17

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DOXORUBICIN	CHEMBL53463	Small molecule	Approval	EMA Human Drugs	5	1	1	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Approval	EMA Human Drugs	12	0	0	Drugs and targets
TOPOTECAN	CHEMBL84	Small molecule	Approval	EMA Human Drugs	3	0	0	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Approval	EMA Human Drugs, at withdrawal	2	0	0	Drugs and targets
TRABECTEDIN	CHEMBL450449	Small molecule	Approval	EMA Human Drugs	2	0	0	Drugs and targets
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Approval	EMA Human Drugs, at withdrawal	1	0	0	Drugs and targets
IFOSFAMIDE	CHEMBL1024	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
IGOVOMAB	CHEMBL2109036	Antibody	Approval	EMA Human Drugs, at withdrawal	1	0	0	Drugs and targets
MELPHALAN	CHEMBL852	Small molecule	Approval	EMA Human Drugs	1	0	0	Drugs and targets
MIRVETUXIMAB SORAVTANSINE	CHEMBL3545132	Antibody drug conjugate	Approval	EMA Human Drugs	1	0	0	Drugs and targets

1 to 10 of 17

See all 17 drugs

Targets24

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PARP1	PARP 1, 2 and 3	3	PARP 1, 2 and 3 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitor	Approval	https://conductscience.org/library/genes/142	Drugs and targets
PARP2	PARP 1, 2 and 3	3	PARP 1, 2 and 3 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor	Approval	https://conductscience.org/library/genes/10038	Drugs and targets
PARP3	PARP 1, 2 and 3	2	PARP 1, 2 and 3 inhibitor	Approval	https://conductscience.org/library/genes/10039	Drugs and targets
TOP2A	DNA topoisomerase 2-alpha	2	DNA topoisomerase II alpha inhibitor	Approval	https://conductscience.org/library/genes/7153	Drugs and targets
TUBA1A	Tubulin	2	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	2	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	2	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	2	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	2	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	2	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7277	Drugs and targets

1 to 10 of 24

See all 24 targets

Trials2

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03663712	Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies	Phase 1	28	2024-11-20	Peritoneal Surface Malignancy	TALIMOGENE LAHERPAREPVEC	Its record names the disease	ClinicalTrials.gov
NCT00189410	Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours	Phase 2	140		Cancer of the Ovary Treated as 2nd Line Therapy, Muellerian Mixed Tumours, Tumours of the Uterus, Cervical Cancers, Non-Epithelial Ovarian Tumours	CARBOPLATIN, DOXORUBICIN	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0021068

GET https://conductscience.org/api/diseases/v1/MONDO_0021068/targets?page=2

API reference For AI assistants